Net sales is up by 23 per cent to Rs 465.2 crore against Rs 378.4 crore in the corresponding quarter last year. Profit before tax up by 46 per cent to Rs 80.8 crore against Rs 55.2 crore in the corresponding quarter last year.
For the year ended March 31, 2014, Alembic's net sales was up by 22 per cent to Rs 1868.4 crore. Net profit after tax for the same period was up by 43 per cent to Rs 235.5 crore. The Board has recommended dividend on equity shares at Rs 3 per share that is 150 per cent for 2013-14.
The India branded formulations business posted sales of Rs 199.5 crores against Rs 175.3 crores with a 14 per cent growth over the corresponding quarter of the previous year. International generic formulation posted growth of 76 per cent and posted sales of Rs 136.7 crore against Rs 77.7 crore over the corresponding quarter last year.
You’ve reached your limit of {{free_limit}} free articles this month.
Subscribe now for unlimited access.
Already subscribed? Log in
Subscribe to read the full story →
Smart Quarterly
₹900
3 Months
₹300/Month
Smart Essential
₹2,700
1 Year
₹225/Month
Super Saver
₹3,900
2 Years
₹162/Month
Renews automatically, cancel anytime
Here’s what’s included in our digital subscription plans
Exclusive premium stories online
Over 30 premium stories daily, handpicked by our editors


Complimentary Access to The New York Times
News, Games, Cooking, Audio, Wirecutter & The Athletic
Business Standard Epaper
Digital replica of our daily newspaper — with options to read, save, and share


Curated Newsletters
Insights on markets, finance, politics, tech, and more delivered to your inbox
Market Analysis & Investment Insights
In-depth market analysis & insights with access to The Smart Investor


Archives
Repository of articles and publications dating back to 1997
Ad-free Reading
Uninterrupted reading experience with no advertisements


Seamless Access Across All Devices
Access Business Standard across devices — mobile, tablet, or PC, via web or app
)